Ticker: BLLN — Exchange: Nasdaq Global Select Market
BillionToOne Stock Price Snapshot (Updated for November 22, 2025)
Although U.S. markets are closed today (Saturday, November 22, 2025), the latest complete trading data for BillionToOne, Inc. (NASDAQ: BLLN) comes from Friday, November 21, 2025:
- Last regular close (Nov 21):$110.00 per share [1]
- Daily move (Nov 21): +14.97% vs. previous close of $95.68 [2]
- Intraday range (Nov 21): $93.00 – $114.25 [3]
- 5‑day performance: +17.87% over the last week, according to MarketBeat’s performance summary [4]
- Approximate market cap: Around $4.3–4.9 billion, based on recent data from StockTitan, Danelfin and Investing.com [5]
- Shares outstanding: ~44.7 million shares [6]
StockTitan’s real‑time dashboard shows BLLN recently quoted around $111.11 in late trading updates dated November 22, 2025, reinforcing that the stock is holding near Friday’s strong close. [7]
In other words, BillionToOne stock is entering the weekend near the upper end of its post‑IPO range, still trading not far below the highs it touched on its first day of trading.
Key News Relevant as of November 22, 2025
There are no new company press releases or major fundamental announcements dated specifically November 22, 2025. However, several fresh data updates and opinions about BLLN are live today and directly relevant to investors following the stock:
- Market data refresh (today):
- MarketBeat, StockTitan, Danelfin and Investing.com all show updated price, market cap and performance metrics as of November 21–22, 2025, confirming the stock closed at $110 with a roughly $4.3–5.0 billion valuation. [8]
- Technical analysis (Investing.com, Nov 22, 2025):
- Investing.com’s technical summary for BLLN is “Strong Buy” on the daily timeframe, with 12/12 moving averages and 8/9 technical indicators flashing Buy, as of Nov 22, 2025 02:47 GMT.
- The 14‑day RSI is ~75, signalling an overbought zone, while volatility (ATR) is elevated, underscoring how hot and volatile this new IPO currently is. [9]
- AI‑driven rating (Danelfin, updated through Nov 22, 2025):
- Danelfin assigns BLLN an AI Score of 1/10 (“Strong Sell”), arguing that the stock has a lower‑than‑average probability of beating the S&P 500 in the next three months, despite its recent surge.
- Danelfin simultaneously reports a market cap of about $4.99 billion and reiterates that BLLN does not pay dividends. [10]
- Media and expert commentary (mid‑November, still very current):
- Jim Cramer recently discussed BillionToOne on Mad Money (summarized by Stockchase on Nov 14, 2025). He praised its genetic‑testing technology, rapid revenue growth and early profitability (EBITDA positive), but flagged IPO‑style volatility and said he’d prefer to buy on a pullback. [11]
- An earlier Insider Monkey summary of Cramer’s remarks notes that he is “a big fan” of the diagnostics space BillionToOne operates in. [12]
So, while there is no brand‑new company press release today, real‑time technical, quant and opinion updates on November 22 paint a picture of a stock that is:
- Technically strong and trending up,
- Fundamentally high‑growth but risky, and
- Viewed cautiously by some AI models and commentators despite the enthusiasm.
How We Got Here: BillionToOne’s Blockbuster IPO
BillionToOne’s story on the market is only a few weeks old, but it’s already dramatic.
- On November 5, 2025, BillionToOne priced its upsized IPO at $60.00 per share, selling 4,551,100 shares of Class A common stock and raising about $273.1 million before any overallotment option. [13]
- The stock began trading on the Nasdaq Global Select Market on November 6, 2025 under the ticker BLLN. [14]
- Major underwriters included J.P. Morgan, Piper Sandler, Jefferies and William Blair, with Stifel, Wells Fargo Securities and BTIG also acting as book‑runners. [15]
On opening day, investor demand was explosive:
- Reuters reports that BLLN opened at $100, far above the $60 offer price, and traded as high as $123.45 before closing around $119.30, a gain of almost 100% in a single session. [16]
- That debut gave BillionToOne an initial valuation around $4.4 billion, putting it in the upper tier of 2025 healthcare IPOs. [17]
Shortly afterward, the company confirmed that it had closed the upsized IPO and the full underwriters’ option, selling 5,233,765 shares in total and raising about $314 million in gross proceeds. [18]
In a year where biotech listings have been tentative, BillionToOne’s IPO has often been cited (by outlets like Reuters and The Wall Street Journal) as a symbol of renewed life‑sciences IPO activity and broader investor interest in precision medicine and diagnostics. [19]
What BillionToOne Actually Does
Behind the ticker, BillionToOne is a precision diagnostics company based in Menlo Park, California, focused on making molecular testing more accurate, efficient and accessible. [20]
Key elements of the business:
- Core technology:
- BillionToOne’s platform is based on single‑molecule next‑generation sequencing (smNGS) and its patented Quantitative Counting Templates (QCT™), which allow it to count individual DNA molecules with very high sensitivity. [21]
- Prenatal diagnostics (UNITY):
- Under the UNITY brand, the company offers non‑invasive prenatal screening tests that can detect chromosomal abnormalities and certain single‑gene disorders from a blood sample. [22]
- Oncology (Northstar):
- Its Northstar offerings are focused on liquid biopsies and cancer monitoring, using cell‑free DNA to track disease progression and treatment response. [23]
- Scale and backing:
Financial Snapshot: High Growth, Narrowing Losses
While BLLN is a brand‑new listing and hasn’t yet reported as a public company, its IPO filing and recent coverage give a useful snapshot of the fundamentals:
- Revenue growth:
- BillionToOne generated $125.5 million in revenue in the first half of 2025, up from $69 million in the same period of 2024 — a jump of around 82% year‑over‑year. [26]
- Profitability trend:
- The company remains loss‑making, but net loss narrowed to $4.2 million for the first six months of 2025, down from $15.2 million a year earlier. [27]
- According to a televised summary captured by Stockchase, BillionToOne’s EBITDA reportedly turned positive earlier this year, suggesting an operating‑level inflection even as GAAP net income remains slightly negative. [28]
- Valuation multiples:
- Investing.com lists a trailing EPS (TTM) of about –$2.99, implying a negative trailing P/E (a reminder that the company is still in investment mode). [29]
- Based on a share price around $110 and a market cap near $4.9 billion, the market is effectively paying up for strong growth and technology differentiation, not current earnings. [30]
In short, BillionToOne looks like a classic high‑growth diagnostics IPO: rapid revenue expansion, improving margins, but still early in the journey toward consistent profitability under standard accounting measures.
This Week’s Move: Why BLLN Rallied Into the Weekend
From Monday to Friday this week (November 17–21, 2025), BLLN staged a sharp rebound:
- Closing prices rose from the low‑$90s to $110, with MarketBeat recording a +17.87% gain over five days. [31]
Several factors appear to be driving the move as of today, November 22:
- Post‑IPO digestion and renewed momentum
After the huge first‑day spike and subsequent pullback, BLLN has been finding a new trading range. The recent bounce suggests investors are warming again to the name now that initial volatility has partially settled. - Technical breakout signals
Investing.com’s dashboard indicates a Strong Buy technical rating for BillionToOne, with:- All short‑ and medium‑term moving averages (MA5 to MA200) in Buy territory, and
- Momentum indicators like MACD, ROC, and Williams %R also flashing bullish as of November 22. [32]
- Quant and AI services putting it on screens
- Danelfin’s Strong Sell (1/10) AI rating and commentary about lower‑than‑average odds of beating the market ironically draw attention to the stock and encourage debate among traders. [33]
- Other platforms tracking IPOs and “hot diagnostics names” have also flagged BillionToOne’s surge and valuation, keeping it in rotation on watchlists. [34]
- Ongoing media coverage and influencer mentions
- Jim Cramer’s partial‑buy stance, praising BillionToOne’s technology and growth but urging patience on entry price, keeps BLLN in the broader retail conversation. [35]
Sentiment Check: Bulls vs. Bears on November 22, 2025
Bullish arguments (as reflected in current data and commentary):
- Massive growth runway: Revenue is growing at double‑digit (and recently triple‑digit) rates, supported by adoption of UNITY prenatal and oncology tests and a broader shift to precision medicine. [36]
- Proprietary tech moat: The QCT™ smNGS platform is repeatedly described as highly differentiated, enabling single‑molecule quantification that could be hard for rivals to replicate. [37]
- Big, expanding TAM: Non‑invasive prenatal testing and liquid biopsy are large, rapidly growing markets with strong tailwinds. [38]
- Early positive operating trends: Narrowing losses and commentary that EBITDA has turned positive suggest operational leverage as volumes scale. [39]
Bearish or cautious arguments:
- Valuation risk: With a market cap close to $5 billion on trailing revenue near the low‑hundreds of millions, BLLN trades at demanding sales multiples, leaving little margin for disappointment. [40]
- IPO‑style volatility: A float representing only a slice of total shares (Cramer has called it a “sliver deal”) means small changes in demand can move the price a lot, in both directions. [41]
- Lock‑up overhang: As with most IPOs, insider and early‑investor lock‑ups typically expire around 180 days after listing, which could introduce selling pressure sometime in 2026, depending on the final terms in the prospectus. [42]
- AI quant view: Danelfin’s AI model sees BLLN as more likely than average to underperform the broader market in the next three months, reinforcing that short‑term risk is significant despite technical strength. [43]
The tension between technical strength and quant scepticism is one of the defining features of BillionToOne’s trading profile as of November 22, 2025.
What Investors Are Watching Next
Looking beyond today, here are the key catalysts and risk factors the market is likely to focus on:
- First earnings as a public company
- The company’s next earnings date hasn’t been formally set on most data pages yet, but its first quarterly report as a public company will be heavily scrutinized for:
- Revenue growth vs. IPO projections
- Gross margin trends
- Cash burn and runway after the $314M raise [44]
- The company’s next earnings date hasn’t been formally set on most data pages yet, but its first quarterly report as a public company will be heavily scrutinized for:
- Post‑IPO trading pattern
- With the IPO only weeks old, investors will monitor whether BLLN stabilizes into a range, continues to rally, or retraces as early momentum cools.
- Regulatory and reimbursement developments
- As a diagnostics company, BillionToOne is exposed to payer reimbursement decisions and regulatory oversight. Positive coverage decisions or new clinical data could be upside catalysts; negative surprises would weigh heavily. [45]
- Competitive landscape
- BLLN competes with other precision‑diagnostics players and established labs. Any new trials, partnerships or M&A in this space (for rivals or for BillionToOne itself) can quickly reshape investor expectations. [46]
- Lock‑up expiration and insider moves
- When lock‑ups eventually expire, insider selling (or a lack of it) will send strong signals about how early backers view the long‑term upside.
Bottom Line for November 22, 2025
As of today:
- BillionToOne stock (BLLN) is trading near $110–$111, up almost 18% this week and still well above its $60 IPO price. [47]
- Technical indicators are firmly bullish, with Investing.com flagging a Strong Buy based on moving averages and momentum, albeit with clearly overbought readings. [48]
- Growth fundamentals look impressive, but the stock carries meaningful valuation and volatility risks, and at least one AI‑driven service currently labels it a Strong Sell on a risk‑adjusted basis. [49]
For readers following BLLN on Google News or Discover, November 22, 2025 is more about confirming the strength of last week’s rally and digesting earlier IPO news than reacting to brand‑new corporate developments. The core narrative remains:
A high‑growth, newly public precision‑diagnostics company with cutting‑edge technology, a multibillion‑dollar valuation, and a stock that is already swinging hard as the market works out what that story is worth.
As always, this article is for informational and news purposes only and is not financial advice. Anyone considering investing in BillionToOne should review the full IPO prospectus (Form S‑1), the company’s official disclosures, and up‑to‑the‑minute market data, and consider speaking with a qualified financial adviser before making trading decisions.
References
1. www.marketbeat.com, 2. www.marketbeat.com, 3. www.investing.com, 4. www.marketbeat.com, 5. www.stocktitan.net, 6. www.stocktitan.net, 7. www.stocktitan.net, 8. www.marketbeat.com, 9. uk.investing.com, 10. danelfin.com, 11. stockchase.com, 12. www.insidermonkey.com, 13. www.globenewswire.com, 14. www.globenewswire.com, 15. www.globenewswire.com, 16. www.reuters.com, 17. www.reuters.com, 18. www.billiontoone.com, 19. www.reuters.com, 20. www.billiontoone.com, 21. www.billiontoone.com, 22. www.billiontoone.com, 23. www.reuters.com, 24. www.billiontoone.com, 25. www.billiontoone.com, 26. www.reuters.com, 27. www.reuters.com, 28. stockchase.com, 29. www.investing.com, 30. www.investing.com, 31. www.marketbeat.com, 32. uk.investing.com, 33. danelfin.com, 34. www.stocktitan.net, 35. stockchase.com, 36. www.reuters.com, 37. www.billiontoone.com, 38. www.reuters.com, 39. www.reuters.com, 40. www.reuters.com, 41. finviz.com, 42. www.globenewswire.com, 43. danelfin.com, 44. www.billiontoone.com, 45. www.reuters.com, 46. www.wsj.com, 47. www.marketbeat.com, 48. uk.investing.com, 49. danelfin.com
